NEW YORK, Feb 18 (Reuters) - Johnson & Johnson said it has recalled two lots of Simponi injection devices -- one in the United States and one in Europe -- after discovering they may deliver less than ...

The Simponi recall stemmed from a manufacturing problem in Switzerland. As Dow Jones reports, many of the affected lots were set aside before hitting the market, but some 395 of the prefilled ...

Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report. A Johnson & Johnson spokesperson said ...

April 27, 2009 — The US Food and Drug Administration (FDA) has approved golimumab (Simponi, Centocor Ortho Biotech Inc) for monthly subcutaneous injection in the treatment of adults with ...

For the third time this week, we're reporting on a Johnson & Johnson recall. (See hereand herefor the other two.) This time the recall seems to involve only a few hundred units. As Dow Jones Newswires ...

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each ...

NEW YORK, Oct 17 (Reuters) - Johnson & Johnson's new rheumatoid arthritis drug, Simponi, when used in combination with the common treatment methotrexate was significantly more effective at inhibiting ...

HONG KONG – Xian Janssen Pharmaceutical Ltd. has launched Simponi (golimumab injection), making it the first once-monthly self-injectable anti-TNF biologic for patients with active ankylosing ...

The US Food and Drug Administration (FDA) today approved a new indication for the tumor necrosis factor (TNF)-alpha inhibitor golimumab (Simponi, Janssen Biotech): treatment of adults with moderate to ...

SIMPONI (Golimumab) 50mg/0.5mL solution for SC inj from Centocor Ortho Biotech The FDA has approved Simponi (golimumab for subcutaneous injection; Janssen Biotech) to induce and maintain clinical ...

European regulators have given clearance to Johnson & Johnson/Schering-Plough’s Simponi for the treatment of three rheumatic conditions: rheumatoid arthritis; psoriatic arthritis; and ankylosing ...